Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Acute Myeloid Leukemia (AML)

 

Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients (2572)
A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia

Investigator: John Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML);    Status: Recruiting;   Study ID: NCT01756677

Liposomal Cytarabine-Daunorubicin CPX-351 for Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (2642)
Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality

Investigator: Roland B. Walter, MD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT01804101

CPX-351 Versus 7+3 for Older Patients (2651)
Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML

Investigator: John Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01696084

Outpatient Induction Chemotherapy for Newly Diagnosed AML or MDS (7910)
Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Investigator: Pamela S. Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT01807091

Decitabine and Cytarabine for Newly Diagnosed AML, High Risk MDS or MPN (9019)
Decitabine plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MDS);    Status: Recruiting;   Study ID: NCT02121418

Tosedostat with Cytarabine or Decitabine for AML
A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS

Investigator: John M. Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01567059